Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 37 articles: HTML format Text format

Single Articles

August 2018
1. HAYFLICK L
   Subject of The Vaccine Race offers perspective on errors.
   Lancet. 2018;392:633-634.
   PubMed     Text format    
   
   
   
2. LEVY Y, Lane C, Piot P, Beavogui AH, et al
   Prevention of Ebola virus disease through vaccination: where we are in 2018.
   Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
   PubMed     Text format    
   
   
   
3. THE LANCET
   Vaccine scandal and confidence crisis in China.
   Lancet. 2018;392:360.
   PubMed     Text format    
   
   
   
4. GREEN A
   HPV vaccine to be offered to boys in England.
   Lancet. 2018;392:374.
   PubMed     Text format    
   
   
   
5. YUAN X
   China's vaccine production scare.
   Lancet. 2018;392:371.
   PubMed     Text format    
   
   
   July 2018
6. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
   Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
   Lancet. 2018;392:232-243.
   PubMed     Text format     Abstract available
   
   
   
7. PAVLAKIS GN, Felber BK
   A new step towards an HIV/AIDS vaccine.
   Lancet. 2018;392:192-194.
   PubMed     Text format    
   
   
   May 2018
8. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
   Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
   Lancet. 2018;391:2116-2127.
   PubMed     Text format     Abstract available
   
   
   
9. CORCORAN B, Clarke A, Barrett T
   Rapid response to HPV vaccination crisis in Ireland.
   Lancet. 2018;391:2103.
   PubMed     Text format    
   
   
   
10. MACARTNEY K, Gershon AA
    Shingles vaccine after auto-HSCT decreases risk.
    Lancet. 2018;391:2082-2084.
    PubMed     Text format    
    
    
    
11. KELLY JD, Mukadi P, Dhillon RS
    Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Lancet. 2018 May 25. pii: S0140-6736(18)31212.
    PubMed     Text format    
    
    
    
12. QADRI F, Azad AK, Flora MS, Khan AI, et al
    Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
    Lancet. 2018;391:1877-1879.
    PubMed     Text format    
    
    
    
13. AGUIAR M
    Dengue vaccination: a more ethical approach is needed.
    Lancet. 2018;391:1769-1770.
    PubMed     Text format    
    
    
    
14. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
    Who is responsible for the vaccination of migrants in Europe?
    Lancet. 2018;391:1752-1754.
    PubMed     Text format    
    
    
    April 2018
15. THE LANCET
    Addressing decreasing vaccine coverage in the EU.
    Lancet. 2018;391:1638.
    PubMed     Text format    
    
    
    March 2018
16. PENG X, Hu X, Salazar MA
    On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
    Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
    PubMed     Text format    
    
    
    
17. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed     Text format    
    
    
    
18. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed     Text format    
    
    
    
19. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed     Text format    
    
    
    February 2018
20. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed     Text format    
    
    
    
21. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed     Text format    
    
    
    
22. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    
    
    
    
23. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    
    
    
    
24. THE LANCET
    Yellow fever: a major threat to public health.
    Lancet. 2018;391:402.
    PubMed     Text format    
    
    
    January 2018
25. THE LANCET
    A new vaccine for typhoid control.
    Lancet. 2018;391:96.
    PubMed     Text format    
    
    
    
26. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Pitfalls of the healthy vaccinee effect - Authors' reply.
    Lancet. 2018;391:123-124.
    PubMed     Text format    
    
    
    
27. MAHMUD SM, Righolt CH
    Pitfalls of the healthy vaccinee effect.
    Lancet. 2018;391:123.
    PubMed     Text format    
    
    
    
28. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
    The polio endgame: securing a world free of all polioviruses.
    Lancet. 2018;391:11-13.
    PubMed     Text format    
    
    
    December 2017
29. MARQUES ETA, Burke DS
    Tradition and innovation in development of a Zika vaccine.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
    PubMed     Text format    
    
    
    
30. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
    Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
    PubMed     Text format     Abstract available
    
    
    
31. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
    Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
    PubMed     Text format     Abstract available
    
    
    October 2017
32. YIN Y
    HPV vaccination in China needs to be more cost-effective.
    Lancet. 2017;390:1735-1736.
    PubMed     Text format    
    
    
    September 2017
33. JIN C, Gibani MM, Moore M, Juel HB, et al
    Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
    PubMed     Text format     Abstract available
    
    
    
34. FEASEY NA, Levine MM
    Typhoid vaccine development with a human challenge model.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
    PubMed     Text format    
    
    
    
35. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
    Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
    PubMed     Text format     Abstract available
    
    
    
36. DENNY L
    Nine-valent human papillomavirus vaccine: great science, but will it save lives?
    Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
    PubMed     Text format    
    
    
    November 2016
37. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
    Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
    Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: